Resveratrol and metabolic

What 2 graded rows on resveratrol agree on for metabolic, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Resveratrol page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Resveratrol page, with its PubMed record.

Supplement

Resveratrol Choose another

2 rows · 438 people

Split. 1 row found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a meta-analysis of 388 people (2014) and reported mixed results.

The rows run from 50 to 388 people, published from 2014 to 2020: 2 pooled reviews and 0 single studies.

1 no difference · 1 mixed

Grade CHbA1c and fasting glucose (Cochrane review) · No difference
Meta-analysis · n 50 · 2020 · Adults with type 2 diabetes in 3 randomized controlled trials
10, 150 or 1,000 mg/day · 4 to 5 weeks
Neutral effects on HbA1c, fasting glucose and insulin resistance (very low-certainty evidence). No adverse events were observed in the three trials.
Row on the Resveratrol page · PubMed 31978258 (opens PubMed)
Grade CFasting glucose, insulin and HbA1c · Mixed
Meta-analysis · n 388 · 2014 · Adults with and without diabetes in 11 randomized controlled trials
Varied; results not affected by dose in subgroup analyses · Varied
No significant effect on glucose measures in people without diabetes. In people with diabetes, fasting glucose, insulin, HbA1c and insulin resistance fell.
Row on the Resveratrol page · PubMed 24695890 (opens PubMed)